{
    "organizations": [],
    "uuid": "4864081f6680a313d7c0be3df6cae1fe822b26bf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novo-nordisk-gets-worldwide-licenc/brief-novo-nordisk-gets-worldwide-licence-to-epidestinys-sickle-cell-disease-programme-idUSC7N1JW01I",
    "ord_in_thread": 0,
    "title": "BRIEF-Novo Nordisk Gets Worldwide Licence To EpiDestiny's Sickle Cell Disease Programme",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 5 (Reuters) - Novo Nordisk A/S:\n* NOVO NORDISK AND EPIDESTINY TODAY ANNOUNCED THAT NOVO NORDISK HAS OBTAINED AN EXCLUSIVE WORLDWIDE LICENCE TO EPIDESTINYâ€™S SICKLE CELL DISEASE (SCD) PROGRAMME, EPI01\n* NOVO NORDISK SAYS EPIDESTINY IS ELIGIBLE TO RECEIVE MORE THAN 400 MILLION US DOLLARS IN UPFRONT, DEVELOPMENT AND SALES MILESTONE PAYMENTS AND WILL GET ROYALTIES ON NET SALES Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)\n ",
    "published": "2018-04-05T20:18:00.000+03:00",
    "crawled": "2018-04-06T21:42:45.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "novo",
        "nordisk",
        "novo",
        "nordisk",
        "epidestiny",
        "today",
        "announced",
        "novo",
        "nordisk",
        "obtained",
        "exclusive",
        "worldwide",
        "licence",
        "epidestiny",
        "sickle",
        "cell",
        "disease",
        "scd",
        "programme",
        "epi01",
        "novo",
        "nordisk",
        "say",
        "epidestiny",
        "eligible",
        "receive",
        "million",
        "u",
        "dollar",
        "upfront",
        "development",
        "sale",
        "milestone",
        "payment",
        "get",
        "royalty",
        "net",
        "sale",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "stine",
        "jacobsen"
    ]
}